Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Stitch Fix Inc (SFIX) vs Sanofi SA (SNY) Price & Performance

Stitch Fix IncTrade

Price performance (Past 24H)

Key statistics

Stitch Fix Inc vs Sanofi SA — how do they compare? Stitch Fix Inc trades at $2.9 (market cap $396.27M), while Sanofi SA trades at $42.7 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 262.6× Stitch Fix Inc's market cap, and Sanofi SA pays a 5.61% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.

SFIXSNY
Market Cap
$396.27M$104.06B
Sector
Consumer CyclicalHealth
52-Week High
$5.80$52.34
52-Week Low
$2.89$41.33
Enterprise Value
$283.99M$124.09B
Dividend Yield
5.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Stitch Fix Inc

Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, as the stock faces technical bearish pressure despite showing fundamental improvements. The company has demonstrated progress in its turnaround with three consecutive quarterly earnings beats and narrowing losses, though it remains unprofitable with a -1.43% net margin. Recent news highlights ongoing legal challenges and AI-driven growth initiatives, while analyst sentiment remains cautious with 64% hold ratings.

The outlook suggests a company in transition - improving operational metrics and debt-free balance sheet provide stability, but sustained profitability remains the key challenge. Near-term catalysts include Q2 2026 earnings results and continued execution of AI personalization strategy, though competitive pressures and consumer spending volatility present ongoing risks.

Sanofi SA

Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.

SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

About Stitch Fix Inc

Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.

Read more on SFIX

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY